• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Superfast TB test slashes waiting time

Shiloh

Editor, Senior Moderator
Source: http://www.nature.com/news/2010/100901/full/news.2010.444.html

Published online 1 September 2010 | Nature | doi:10.1038/news.2010.444


Superfast TB test slashes waiting time

Infection with tuberculosis can be diagnosed easily and accurately in less than two hours.

Apoorva Mandavilli
TB bacteriaThe new test not only identifies TB in 98% of cases, but also detects resistance to rifampicin, a first-line TB drug.KWANGSHIN KIM / SCIENCE PHOTO LIBRARY

A new test can accurately diagnose tuberculosis (TB) in people in 90 minutes, compared with the six weeks needed for the current standard test.

The Xpert MTB/RIF test, described today in the New England Journal of Medicine1, identifies TB in 98% of active cases ? an improvement of more than 45% on one of the most commonly used current techniques. It also detects whether the TB-causing bacteria are resistant to rifampicin, a first-line drug for TB, in nearly 98% of cases.

"It has the potential to be revolutionary," says Richard Chaisson, director of the Johns Hopkins Center for Tuberculosis Research in Baltimore, Maryland, who was not involved with the work...
 
Back
Top Bottom